Merck & Company Inc (MRK)vsTiziana Life Sciences Ltd (TLSA)
MRK
Merck & Company Inc
$110.95
-1.60%
HEALTHCARE · Cap: $274.03B
TLSA
Tiziana Life Sciences Ltd
$1.28
+1.59%
HEALTHCARE · Cap: $159.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates -1808473% more annual revenue ($65.01B vs $-3.60M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TLSA
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Intrinsic value data unavailable for TLSA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Trading at 16.0x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TLSA
TLSA has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TLSA
The primary concerns for TLSA are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
TLSA carries more volatility with a beta of 0.37 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 16/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Tiziana Life Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?